|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||1.8000 - 1.9000|
|52 Week Range||0.3100 - 4.8900|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
REHOVOT, ISRAEL, July 06, 2020 -- via NEWMEDIAWIRE ‒ Meridian HSN has partnered with Moto-Para and Todos Medical (OTCQB: TOMDF) to provide a complete turnkey solution for.
REHOVOT, Israel, NEW YORK, NY and BOULDER, CO, June 29, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Todos Medical Ltd. (TOMDF), an in vitro diagnostics company focused on the distribution of a comprehensive suite of solutions for the screening and diagnosis of COVID-19 and the development of blood tests for the early detection of cancer and Alzheimer’s disease, today announced that it has entered into a partnership with Meridian Health Services Network (“Meridian,” www.meridianhsn.com) to deploy COVID-19 testing programs throughout the United States. As part of the agreement, Todos will be working closely with Meridian to help supplement COVID-19 testing products and services for its network of brick & mortar and mobile laboratories nationwide.
Emerald Organic Products, Inc. (OTC: EMOR) (the “Company”, "Emerald Organic", or "Emerald Organic Products"), a diversified health sciences company, is pleased to announce the launch of Emerald Shield™, an all-encompassing solution developed to facilitate necessary initiatives in a safety-conscious post-COVID-19 world. With a mission to support communities, companies, and municipalities across the United States, Emerald Shield’s key focus areas are its technologically-driven public safety solutions, and transformative health and wellness platforms. As communities reopen, businesses and government agencies are actively seeking effective ways to keep the state safe by working with companies like Emerald Shield who specialize in sanitizing solutions.
REHOVOT, Israel, and NEW YORK, June 16, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Todos Medical Ltd. (TOMDF), an in vitro diagnostics company focused on the distribution of a comprehensive suite of solutions for the screening and diagnosis of COVID-19 and the development of blood tests for the early detection of cancer and Alzheimer’s disease, today announced that it has entered into an exclusive worldwide distribution agreement with Israel-based NLC Pharma to commercially develop its patented virus-focused 3C Protease diagnostic platform for the diagnosis of COVID-19. “3C Protease quantitation presents a unique approach to viral replication monitoring, and could prove to be a significant tool in the fight against COVID-19,” said Jorge Leon, PhD, Senior Medical Advisor to Todos.
· Exclusive Distribution agreement covers North America, Latin America, SE Asia, Europe · Validation of Gnomegen qPCR kits now complete at CLIA/CAP-certified.
HOLBROOK, NY, REHOVOT, ISRAEL, SINGAPORE AND NEW YORK, NY, May 08, 2020 -- Emerald Organic Products, Inc. (OTC: EMOR) ("Emerald") a diversified health sciences and technology.
Emerald Organic Products, Inc. (OTC: EMOR) (the “Company”, "Emerald", "Emerald Organic", or "Emerald Organic Products") a diversified health sciences and technology company, is pleased to announce that the Company has successfully completed its product pilot for NxGen Hand Sanitizer (the “Product Pilot”), selling out thousands of bottles within one week of launch. “The great reception we received from the market for our NxGen hand sanitizer Product Pilot tells us that we are in the right sector, with the right product,” commented Ian Parker, Chief Executive Officer of Emerald Organic Products.
Emerald Organic Products, Inc. (OTC: EMOR) (the “Company”, "Emerald", "Emerald Organic", or "Emerald Organic Products") a diversified health sciences company, is pleased to announce that subsequent to the Company’s press release on March 27, 2020 regarding Emerald’s acquisition of a 51% controlling stake in Bonsa Health (the “Acquisition”), Bonsa Health has announced four new prescription delivery partnerships (the “Partnerships”), highlighting the platform’s rapid growth and expansion as the demand for same-day delivery of prescriptions and medications has increased dramatically due to self-quarantining and self-isolation amid the COVID-19 pandemic.
Gibraltar Brothers & Associates, LLC has entered into agreements with Gnomegen, LLC to supply Todos with its proprietary Real Time digital PCR Test Kits for COVID-19.
REHOVOT, Israel, SINGAPORE and NEW YORK, NY, April 17, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE --Todos Medical Ltd. (TOMDF), a commercial in vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders as well as point-of-care and lab-based tests for COVID-19, announces the appointment of Lauren Chung, Ph.D. to its Board of Directors. This appointment increases the size of the Todos Medical Board to 7 Directors, including 2 independent Directors. Dr. Chung has been named lead independent Director, and will serve as Chair of both the Compensation Committee and the Nomination and Governance Committee.
REHOVOT, Israel, SINGAPORE and NEW YORK, NY, April 15, 2020 -- via NEWMEDIAWIRE -- Todos Medical Ltd. (OTCQB: TOMDF), a commercial in vitro diagnostics company focused on the.
REHOVOT, ISRAEL, SINGAPORE and NEW YORK, NY, April 09, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Todos Medical Ltd. (TOMDF), a pre-commercial stage in vitrodiagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, announces that its President and Chief Executive Officer Gerald E. Commissiong has provided the following corporate update on the Company’s ongoing initiatives, including progress with its novel coronavirus (COVID-19) joint venture Corona Diagnostics, LLC, the ongoing breast cancer commercialization trial with its proprietary blood spectroscopy platform, and the pending acquisition of its Alzheimer’s disease joint venture Breakthrough Diagnostics, Inc. Through our entities and teams in the U.S., Israel and Singapore, we are working through the various regulatory and international import/export requirements in order to initiate sales in the United States and abroad.
Emerald Organic Products Inc. (OTC: EMOR) ("Emerald" or the "Company") a high growth diversified health science and technology company, today has entered into a definitive agreement to acquire Carie Health Inc. (“Carie”), a leading telehealth and virtual care technology and service solutions company. “Founded in 2016, Carie has quickly matured into a fully-proprietary end-to-end telehealth solution capable of scaling up to lead America’s transition to a more consumer friendly, virtual healthcare model,” said Matt Wanderer, Founder and CEO of Carie Health.
Todos expands rights to include Asian countries and to include PCR test kits Corona Diagnostics JV with Emerald Organic responsible for commercialization Dr. Joseph Wee,.
In the age of technological advances and need for modern convenience, Bonsa offers an all encompassing tech-driven digital solution that creates an effective, secured communication line between providers, patients, and pharmacists to expedite prescription fulfillment and same day delivery. Bonsa is expecting to enhance its current same-day delivery to offer 3-hour national delivery by January 2021.
Emerald Organic Products, Inc. (OTC: EMOR) and Todos Medical Ltd. (OTCQB: TOMDF) today announced the creation of Corona Diagnostics, LLC, a joint venture partnership formed to address the much-needed demand for COVID-19 screening and diagnostic testing in the United States. The joint venture will be owned 51% by Emerald and 49% by Todos.
Alliance has been in the equipment leasing sector since 1998 and financed well over $2B+ in assets to 25,000+ businesses throughout the United States. With 100+ employees and offices in Orange County, Los Angeles and Portsmouth, NH, Alliance has the scale to address the needs of OEM’s and distributors of all sizes while also providing the flexibility of an entrepreneurial equipment lessor.
Bedrock is a private equity firm focused on providing growth capital to select emerging growth companies. Under the terms of the agreement, Bedrock will be entitled to covert its $5M in Series C Preferred Stock investment into common shares of the Company at a fixed price of $1.60. “After working with Emerald Organic’s management team over the last several months, we believe we have finally found the right leadership group to make our first investment in the hemp space,” said J. Roth, Manager of Bedrock.
Emerald gains exclusive worldwide development rights to ESS, MANF and PhenoGuard Amarantus receives Emerald preferred stock valued at a minimum of $66.6 million New.
Holbrook, New York, Nov. 11, 2019 -- Emerald Organic Products, Inc. (OTC:EMOR) (“Emerald” or the “Company”), a diversified cannabidiol (“CBD”) products company, is pleased to.
Portfolio includes treatments for Alzheimer's disease, ADHD, Parkinson's disease, vision loss and severe burns Amarantus to receive Emerald Organics Preferred Stock for the exclusive worldwide license ...
NEW YORK, NY, Oct. 24, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (“Amarantus,” or AMBS), a US-based JLABS-alumnus biotechnology holding company developing proprietary orphan neurologic, regenerative medicine and ophthalmic therapies and diagnostics through its subsidiaries, today announced it has entered into a binding term sheet to license its therapeutic assets to Emerald Organic Growth, Inc. (EMOR) (“Emerald” or EMOR), a fully-integrated, CBD-based health sciences company launching branded products via its nationwide distribution channels. Amarantus will receive Emerald Preferred Stock to be valued at a minimum of $100M in 2022, and up to double digit royalties (in addition to passthrough royalties and milestones) in exchange for worldwide, exclusive development and commercial rights to eltoprazine, engineered skin substitute (ESS), mesencephalic astrocyte-derived neurotrophic factor (MANF) and PhenoGuard.
Holbrook, New York, Sept. 30, 2019 -- Emerald Organic Products, Inc. (OTC:EMOR) (“Emerald” or the “Company”) is pleased to announce the addition of former Quest Nutrition, LLC.
Holbrook, NY, Sept. 17, 2019 -- Emerald Organic Products, Inc. (OTC:EMOR) (“Emerald” or the “Company”) is pleased to announce that its Watermelon Pura CBD Gummy Rings, produced.
Emerald Organic Products, Inc. (OTC:EMOR) (“Emerald” or the “Company”) is pleased to announce that it has formally entered into an exclusive licensing agreement for the use of OraPatch™, a patented oral delivery method for various substances including caffeine and cannabidiol (“CBD”) from PetVivo Holdings, Inc. (OTC:PETV) (“PetVivo”). Furthermore, the OraPatch product only uses materials deemed to be Generally Recognized as Safe (“GRAS”) by the United States Food and Drug Administration (the “FDA”). John Lai, President of PetVivo said, “We were waiting for the right consumer branding team to license this extraordinary, cutting edge technology to.